CASTLE BIOSCIENCES INC CSTL
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
3/9
Piotroski F — financial health
6.15
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $344.2M | -$24.2M | — | $28.3M | $470.9M |
| 2024 | $332.1M | $18.2M | — | $36.5M | $455.8M |
| 2023 | $219.8M | -$57.5M | — | -$19.2M | $391.3M |
| 2022 | $137.0M | -$67.1M | — | -$47.3M | $399.1M |
| 2021 | $94.1M | -$31.3M | — | -$22.5M | $411.7M |
| 2020 | $62.6M | -$10.3M | $53.0M | $5.1M | $415.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Oelschlager Kristen M | Chief Operating Officer | 2026-06-16 | Sell | 8,587 | $20.71 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Sell | 550 | $20.66 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Sell | 278 | $20.66 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Sell | 1,153 | $20.66 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Sell | 278 | $20.66 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Sell | 278 | $20.66 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Sell | 1,357 | $20.66 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer | 2026-06-15 | Option exercise | 550 | $2.39 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.15 (safe)
- Working capital / assets 0.505
- Retained earnings / assets -0.388
- EBIT / assets -0.074
- Equity / liabilities 4.373
Source: SEC EDGAR filings · CIK 0001447362 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.